Story excerpt provided by Cincinnati Enquirer.
Written by Anne Saker.
Doreen Schowalter of Mason created marketing campaigns for Procter & Gamble and other companies, cooked with a chef’s touch and was happily married with three children. She was outgoing and social ‑ the last person, she believed, to develop depression.
But in 2009, amid a crisis with heart disease, Schowalter, 62, turned lethargic, disinterested and despairing, unable to move from a chair or her bed all day. “I was getting treated by very good doctors, and I was prescribed a lot of different medications. Nothing worked,” she said. “I had a sadness depression. I felt I was slipping away.”
Nearly out of hope, Schowalter took a then-experimental test that aimed to match her genetic profile to the chemical makeup of depression-lifting pharmaceuticals. With the test results, her doctor created a treatment plan that “brought me back to life again.”
Schowalter was on the leading edge of depression treatment in taking the GeneSight test, manufactured by Assurex Health Inc. of Mason. The company is a biotech offspring of Cincinnati Children’s Hospital Medical Center and the Mayo Clinic.
Click here to read the complete article.
Originally published March 14, 2016.